High-frequency migraine refractory to usual pharmacological treatment and antibody and responsive to full-spectrum cannabidiol: a case report

Authors

DOI:

https://doi.org/10.48208/HeadacheMed.2022.26

Keywords:

Migraine, Cannabidiol, Pain

Abstract

The use of derivatives of Cannabis sp. in the treatment of certain medical conditions, such as neuropathic pain, epilepsy and multiple sclerosis, is well known. However, studies on its benefit in headache are low in scope, consisting, in majority, of reports and case series. We report the case of a 74-year-old male patient with high frequency migraine (2 to 3 times/week) for several years, presenting important functional limitation associated with several triggers, and using triptans for headache crisis only. The patient expressed intolerance to 2 prophylactic drugs (topiramate and propranolol). He performed 2 applications of Erenumab 70 mg, wich promoted considerable initial improvement followed by a new increase in attacks’ frequency after the second application, leading to interruption of this therapy. Nutraceuticals were tried for 6 months, but there was not any improvement. After the introduction of cannabidiol oil, migraine attacks reduced in frequency (1 episode/month) and intensity, with a record interval of 30 consecutive days without pain, associated with elimination of triggers. Preclinical studies evaluating the relationship between endocannabinoid system and migraine pathophysiology point to Cannabis sp. derivatives as potential weapons for the treatment of this condition. However, the role of these derivatives as prophylaxis of migraine attacks is still speculative, thus requiring controlled studies for further definition.

Downloads

Download data is not yet available.

References

James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, . . . Murray CJL. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet 2018;392(10159):1789-1858 Doi:10.1016/s0140-6736(18)32279-7 DOI: https://doi.org/10.1016/S0140-6736(18)32279-7

Lochte BC, Beletsky A, Samuel NK and Grant I. The Use of Cannabis for Headache Disorders. Cannabis and Cannabinoid Research 2017;2(1):61-71 Doi:10.1089/can.2016.0033 DOI: https://doi.org/10.1089/can.2016.0033

Baron EP. Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science. Headache: The Journal of Head and Face Pain 2018;58(7):1139-1186 Doi:10.1111/head.13345 DOI: https://doi.org/10.1111/head.13345

Poudel S, Quinonez J, Choudhari J, Au ZT, Paesani S, Thiess AK, . . . Michel J. Medical Cannabis, Headaches, and Migraines: A Review of the Current Literature. Cureus 2021;Doi:10.7759/cureus.17407 DOI: https://doi.org/10.7759/cureus.17407

Cabral GA, Rogers TJ and Lichtman AH. Turning Over a New Leaf: Cannabinoid and Endocannabinoid Modulation of Immune Function. Journal of Neuroimmune Pharmacology 2015;10(2):193-203 Doi:10.1007/s11481-015-9615-z DOI: https://doi.org/10.1007/s11481-015-9615-z

Kazemi H, Rahgozar M, Speckmann EJ and Gorji A. Effect of cannabinoid receptor activation

on spreading depression. Iran J Basic Med Sci 2012;15(4):926-936,

Shibata M and Suzuki N. Exploring the role of microglia in cortical spreading depression in neurological disease. Journal of Cerebral Blood Flow & Metabolism 2017;37(4):1182-1191

Doi:10.1177/0271678x17690537 DOI: https://doi.org/10.1177/0271678X17690537

Rossi C, Pini LA, Cupini ML, Calabresi P and Sarchielli P. Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels. European Journal of Clinical Pharmacology 2007;64(1):1-8 Doi:10.1007/s00228-007-0391-4 DOI: https://doi.org/10.1007/s00228-007-0391-4

Borgdorff P and Tangelder GJ. Migraine: Possible Role of Shear-Induced Platelet Aggregation With Serotonin Release. Headache: The Journal of Head and Face Pain 2012;52(8):1298-1318 Doi:10.1111/j.1526-4610.2012.02162.x DOI: https://doi.org/10.1111/j.1526-4610.2012.02162.x

Volfe Z, Dvilansky A and Nathan I. Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients. Int J Clin Pharmacol Res 1985;5(4):243-246,

Akerman S, Holland PR, Lasalandra MP and Goadsby PJ. Endocannabinoids in the Brainstem Modulate Dural Trigeminovascular Nociceptive Traffic via CB1 and "Triptan" Receptors: Implications in Migraine. Journal of Neuroscience 2013;33(37):14869-14877 Doi:10.1523/jneurosci.0943-13.2013 DOI: https://doi.org/10.1523/JNEUROSCI.0943-13.2013

Akerman S, Kaube H and Goadsby PJ. Anandamide Is Able to Inhibit Trigeminal Neurons Using an in Vivo Model of Trigeminovascular-Mediated Nociception. Journal of Pharmacology and Experimental Therapeutics 2004;309(1):56-63 Doi:10.1124/jpet.103.059808 DOI: https://doi.org/10.1124/jpet.103.059808

Russo EB. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis and Cannabinoid Research 2016;1(1):154-165 Doi:10.1089/can.2016.0009 DOI: https://doi.org/10.1089/can.2016.0009

Downloads

Published

2022-09-30

How to Cite

1.
Rosa LMM, Araújo Siega MR de. High-frequency migraine refractory to usual pharmacological treatment and antibody and responsive to full-spectrum cannabidiol: a case report. Headache Med [Internet]. 2022 Sep. 30 [cited 2024 Dec. 4];13(3):229-32. Available from: https://headachemedicine.com.br/index.php/hm/article/view/661

Issue

Section

Case Report

Similar Articles

You may also start an advanced similarity search for this article.